A. Giatromanolaki et al., Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas, CLIN EXP M, 18(4), 2000, pp. 313-319
Vascular endothelial growth factor (VEGF) and its receptors, Flt-1 and flk-
1(KDR), constitute an important angiogenic pathway which, under hypoxic con
ditions, is up-regulated in many solid tumours. We used the monoclonal anti
body 11B5, specific for recognizing VEGF expression and the `VEGF/flk-1(KDR
) complex' on tumour endothelium, to assess free VEGF protein expression an
d VEGF/receptor activated microvessel density (aMVD) in a series of 104 ino
perable locally advanced squamous cell carcinomas of the head and neck, tre
ated with chemo-radiotherapy. High VEGF expression in cancer cells was stro
ngly associated with high VEGF/receptor expression in the vasculature. The
high VEGF expression and the aMVD were not associated with the standard mic
rovessel density (sMVD), as assessed with the monoclonal antibody anti-CD31
and, were not detected in normal tissue. An increased sMVD, however, was s
ignificantly related with the expression thymidine phosphorylase (TP), and
also with the nuclear accumulation of the oncoprotein p53, but neither p53
nor TP was associated with VEGF expression by cancer cells or VEGF/receptor
complex aMVD. In 35% of cancer cases examined, more than 20% of the microv
essels assessed with anti-CD31 also expressed the VEGF/KDR complex. The vas
culature of the normal head and neck mucosa did not express the VEGF/KDR co
mplex. There was no association between VEGF expression or VEGF/receptor co
mplex aMVD and response to chemo-radiotherapy or patient's survival. It is
concluded that activation of the angiogenic pathway VEGF/flk-1(KDR) is tumo
r specific in a subgroup of locally advanced squamous cell carcinomas of th
e head and neck. Selective destruction of this type of vasculature, using i
mmunoconjugates directed against the VEGF/receptor complex, may prove thera
peutically useful for patients with a high tumoral VEGF/flk-1(KDR) activate
d microvessel fraction.